a. Clinical evaluation, including vital signs and weight, symptom assessment and ECOG scoring. 2. Patients of child bearing potential must have a negative urine pregnancy test. 3. CBC (complete blood count with differential and platelet count), serum chemistries (electrolytes, AST, ALT, alkaline phosphatase, bilirubin, creatinine and blood urea nitrogen (BUN)). 4. Obtain up to 110 mls peripheral blood for research studies, prior to second booster vaccination. 5. A FDG -PET scan will be performed prior to the second booster vaccination. 6. Vaccination will be administered i.d. at the site of previous vaccination. 7. Post immunization monitoring: T he patients will be observed for at least 60 minutes post immunization. Vital signs will be done at least 60 minutes post vaccination. D. 48 hours after Booster Vaccination #2 1. Delayed type hypersensitivity (DTH) will be evaluated at the injection site app roximately 48 hours (+24 hours) after the booster vaccine and the DTH response (i.e. induration and erythema) measured in mm2.